An Evaluation of Treatment Outcomes in a Cohort of Clients on the DOTS Strategy, 2012–2016
Table 3
Pretreatment sputum smear grade and treatment outcome among clients.
Pretreatment sputum smear grade (%)
Total
Negative
Scanty (sc)
(1+)
(2+)
(3+)
Age range (years)
<10
2 (0.9)
—
—
—
—
2
10–19
4 (1.9)
1 (0.5)
2 (0.9)
1 (0.5)
3 (1.4)
11
20–29
9 (4.2)
2 (0.9)
4 (1.9)
8 (3.8)
12 (5.6)
35
30–39
17 (8.0)
4 (1.9)
3 (1.4)
10 (4.7)
10 (4.7)
44
40–49
16 (7.5)
4 (1.9)
13 (6.1)
4 (1.9)
14 (6.6)
51
50–59
17 (8.0)
5 (2.3)
6 (2.8)
4 (1.9)
8 (3.8)
40
≥60
22 (10.3)
—
—
2 (0.9)
6 (2.8)
30
Total
87 (40.8)
16 (7.5)
28 (13.1)
29 (13.6)
53 (24.9)
213
Sex
Female
25 (11.7)
6 (2.8)
4 (1.9)
7 (3.3)
12 (5.6)
54
Male
62 (29.1)
10 (4.7)
24 (11.3)
22 (10.3)
41 (19.2)
159
Total
87 (40.8)
16 (7.5)
28 (13.1)
29 (13.6)
53 (24.9)
213
Treatment outcome
Cured
—
13 (6.1)
25 (11.7)
27 (12.7)
45 (21.1)
110 (51.6)
Completed
80 (37.6)
—
—
—
—
80 (37.6)
Treatment failure
—
1 (0.5)
2 (0.9)
—
—
3 (1.4)
Lost to follow-up
1 (0.5)
—
—
1 (0.5)
—
2 (0.9)
Died at home
6 (2.8)
2 (0.9)
1 (0.5)
1 (0.5)
7 (3.3)
17 (8.0)
Died at Chest Ward
—
—
—
—
1 (0.5)
1 (0.5)
Total
87 (40.8)
16 (7.5)
28 (13.1)
29 (13.6)
53 (24.9)
213
Negative: no Acid-Fast Bacilli (AFB) seen in at least 100 fields; scanty (sc): 1–9 AFB found in 100 fields; (1+): 10–99 AFB found in 100 fields; (2+): 1–10 AFB found per field in at least 50 fields; (3+): more than 10 AFB per field in at least 20 fields.
